Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 284 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Type 1 interferon Clear all

Conditions: Liver Cancer
Interventions: recombinant interferon alfa, thalidomide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: Avonex/Zocor; Drug
Lead sponsor: University of North Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions: New Formulation of rebif - human interferon beta-1a, Interferon beta -1b; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Adult Solid Neoplasm
Interventions: Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine, Sargramostim; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Anifrolumab, Standard of Care; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more

Conditions: Insulin-Dependent Diabetes Mellitus
Interventions: 30,000 units hrINF-alpha, 5,000 hrINF-alpha, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 3 Years to 25 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 5
States / cities: Bethesda, Maryland • Saint Paul, Minnesota • Kansas City, Missouri + 2 more

Conditions: Melanoma (Skin)
Interventions: recombinant interferon alfa, thalidomide; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 94
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: HIV Infections, Hepatitis C
Interventions: Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 24
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: HIV Infections
Interventions: Interferon alfa-2a, Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 4
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 1 more

Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Interventions: recombinant interferon alfa, thalidomide, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2a, Zidovudine, Interferon alfa-n1; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, recombinant interferon alfa, cisplatin, cyclophosphamide, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Robert H. Lurie Cancer Center; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b; Drug
Lead sponsor: Teva Neuroscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Swartz Creek, Michigan • Columbus, Ohio • Carnegie, Pennsylvania

Conditions: Leukemia
Interventions: recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, imatinib mesylate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Duarte, California • Seattle, Washington

Conditions: Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 276
States / cities: Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 184 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Melanoma (Skin)
Interventions: interferon alfa-2b, observation; Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2026
U.S. locations: 511
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 354 more

Conditions: Multiple Sclerosis
Interventions: Interferon-beta-1b (BETASERON, BAY 86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma, Hypernephroid
Interventions: RAD001(everolimus), interferon alfa-2a, bevacizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 5 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: IFN-β-1a (Rebif®); Drug
Lead sponsor: Waukesha Memorial Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Interferon beta 1-a, glatiramer acetate, placebo; Drug · Other
Lead sponsor: Fred Lublin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1,008 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 48
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 43 more

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: melphalan, recombinant interferon alfa, aldesleukin, in vitro-treated peripheral blood stem cell transplantation; Drug · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HLA-A2 Positive Cells Present, Refractory Melanoma
Interventions: Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor, PD1 Inhibitor, Recombinant Interferon Alfa-2b, Rintatolimod; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

RNF and Betaseron® Tolerability Study

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

Interferon-Alpha for Diabetes Mellitus Type 1

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Therapy Optimization in Multiple Sclerosis (MS)

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma